Assessing the sexual consequences of focal therapy for localised prostate cancer

ISRCTN ISRCTN11634296
DOI https://doi.org/10.1186/ISRCTN11634296
IRAS number 278558
Secondary identifying numbers IRAS 278558
Submission date
16/09/2020
Registration date
18/09/2020
Last edited
23/11/2021
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Prostate cancer is a form of cancer that develops in the prostate gland. Focal therapy involves treating just the cancer, while leaving the rest of the prostate and surrounding tissue intact. The aim of this study is to collect information about changes in men's sexual function after focal therapy to provide men with accurate information they can use when deciding which treatment to choose.

Who can participate?
Men who were treated for prostate cancer with irreversible electroporation (IRE) in the past 2 years can be enrolled in the retrospective arm of the study. Men who will be treated for prostate cancer with focal therapy with high-intensity focused ultrasound (HIFU), cryotherapy or IRE can take part in the prospective arm.

What does the study involve?
Men in the retrospective arm will be asked to fill in questionnaires about the quality of their erections and ejaculation. A telephone interview will be organised to collect more in-depth data about the changes in their sexual function after the treatment (covering topics such as erection, ejaculation, orgasm, changes in the size or shape of the penis, etc).
Men in the prospective arm will have an evaluation before surgery using the same questionnaires, and a first telephone interview to record their expectations. Another evaluation including questionnaires and a second telephone interview will be scheduled 3 months after surgery to collect more in-depth data about the changes in their sexual function after the treatment (covering topics such as erection, ejaculation, orgasm, changes in the size or shape of the penis, etc).

What are the possible benefits and risks of participating?
The researchers will try to accommodate patients' schedule to minimise the inconvenience in taking part in the interviews. Participants may worry about experiencing some discomfort discussing intimate matters with a researcher. The study team will make sure that the training of the interviewer and interview methods used allow men to feel at ease during the interview. Participants will receive compensation in the form of £40 vouchers and will help future patients benefit from more accurate information before treatment.

Where is the study run from?
University College London (UK)

When is the study starting and how long is it expected to run for?
April 2020 to February 2022 (updated 17/05/2021, previously: August 2021)

Who is funding the study?
Angiodynamics (USA)

Who is the main contact?
Gaelle Fiard
g.fiard@ucl.ac.uk

Contact information

Mrs Gaelle Fiard
Scientific

Division of Surgery and Interventional Science
University College London
3rd Floor, Charles Bell House
43-45 Foley Street
London
W1W 7TS
United Kingdom

ORCiD logoORCID ID 0000-0003-3049-5318
Phone +44 (0)7568764334
Email g.fiard@ucl.ac.uk

Study information

Study designMixed-methods study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Other
Study typeQuality of life
Participant information sheet ISRCTN11634296_PIS_retrospective_V2.0_28Aug20.docx
Scientific titleSexual Assessment after Focal therapy with various Energy sources (SAFE): a mixed-methods study
Study acronymSAFE
Study objectivesFocal therapy has arisen as a promising tissue-preserving treatment option for men with localised prostate cancer, offering to better preserve men's genito-urinary function. However, most of the evaluation of function has taken place at a relatively high, non-granular level. However, most of the data used to provide informed consent for patients is obtained from retrospective – usually single-centre – series, or derived from prospective studies whose primary outcome was oncological. The aim of the SAFE study is to address this need by collecting in-depth details of men's sexual function after focal therapy with various energy sources, using qualitative research methods and validated questionnaires.
Ethics approval(s)Approved 02/09/2020, North West - Greater Manchester West Research Ethics Committee (Barlow House 3rd Floor, 4 Minshull Street, Manchester M1 3DZ, +44 (0)2071048285; gmwest.rec@hra.nhs.uk), REC ref: 20/NW/0335
Health condition(s) or problem(s) studiedLocalised prostate cancer treated with focal therapy
Intervention1. Self-administered validated questionnaires
2. Semi-structured telephone interviews

Men in the retrospective arm will be asked to fill in validated questionnaires exploring and quantifying the quality of their erections and ejaculation. A telephone interview will be organised to collect more in-depth data about the evolution of their sexual function after the treatment (covering topics such as erection, ejaculation, orgasm, changes in the size or shape of the penis, etc).

Men in the prospective arm will have a baseline evaluation before surgery, using the same questionnaires, and a first telephone interview to record their expectations. Another evaluation including questionnaires and a second telephone interview will be scheduled 3 months after surgery to collect more in-depth data about the evolution of their sexual function after the treatment (covering topics such as erection, ejaculation, orgasm, changes in the size or shape of the penis, etc).
Intervention typeBehavioural
Primary outcome measureQualitative sexual outcomes gathered using semi-structured telephone interviews at 3 months after focal therapy (prospective cohort)
Secondary outcome measures1. Preoperative patients' expectations assessed using semi-structured telephone interviews at baseline (or before treatment)
2. Qualitative sexual outcomes gathered using semi-structured telephone interviews at various time points ranging from 6 months and 24 months after surgery (retrospective arm - the researchers will select patients to cover as many timepoints as possible but don’t know yet which ones precisely)
3. Erectile function measured by IIEF-15 at baseline and 3 months
4. Ejaculatory function measured by MSHQ-EjD-SF at baseline and 3 months
Overall study start date03/04/2020
Completion date28/02/2022
Reason abandoned (if study stopped)Lack of staff/facilities/resources

Eligibility

Participant type(s)Patient
Age groupAdult
SexMale
Target number of participants50
Key inclusion criteriaRetrospective cohort:
1. Men treated with focal IRE in the last 24 months agreeing to be approached after receiving the invitation letter
2. Preoperative normal sexual function (retrospective)
3. Signed informed consent by the patient

Prospective cohort:
1. Men with a histological diagnosis of prostate cancer on trans-rectal or transperineal template prostate biopsies
2. Gleason score ≤7
3. Clinical stage ≤T2cNoMo (radiological T3a allowed)
4. Serum PSA ≤15ng/ml
5. Local staging imaging as per guidelines to demonstrate localised disease (this may include MRI, CT, bonescan or functional imaging)
6. MRI-visible unilateral or anterior disease accessible to focal HIFU, cryotherapy or IRE
7. Baseline potency with erections sufficient for penetration
8. Signed informed consent by the patient
Key exclusion criteriaRetrospective cohort:
1. Men with preoperative (remembered) altered sexual function or no sexual activity
2. Salvage treatment
3. Non-English readers and speakers
4. Vulnerable men unable to provide informed consent

Prospective cohort:
1. Men with baseline erectile dysfunction and erections insufficient for penetration
2. Men who had prostate surgery for cancer control e.g., radical prostatectomy, HIFU, cryosurgery, photodynamic therapy
3. Men undergoing whole-gland treatment
4. Non-English readers and speakers
5. Vulnerable men unable to provide informed consent
Date of first enrolment25/09/2020
Date of final enrolment30/11/2021

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

University College London Hospitals NHS Foundation Trust
250 Euston Road
London
NW1 2PG
United Kingdom
London Urology Specialists
Emmanuel Kaye House
37 Devonshire Street
London
W1G 6QA
United Kingdom

Sponsor information

University College London
University/education

Joint Research Office
UCL Gower Street
London
WC1E 6BT
England
United Kingdom

Phone +44 (0)203 447 5696
Email UCLH.randd@nhs.net
Website http://www.ucl.ac.uk/
ROR logo "ROR" https://ror.org/02jx3x895

Funders

Funder type

Industry

AngioDynamics

No information available

Results and Publications

Intention to publish date28/02/2023
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal. The protocol will be submitted for publication shortly.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Gaelle Fiard (g.fiard@ucl.ac.uk). Anonymised data can be made available and patients will be consenting to it. Anonymised scores on validated questionnaires and transcripts can be obtained for verification purposes.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version V2.0 28/08/2020 08/10/2020 No Yes
Participant information sheet version V2.0 28/08/2020 08/10/2020 No Yes
Protocol file version V1.0 29/06/2020 08/10/2020 No No
HRA research summary 28/06/2023 No No

Additional files

ISRCTN11634296_PROTOCOL_V1.0_29June20.pdf
Uploaded 08/10/2020
ISRCTN11634296_PIS_retrospective_V2.0_28Aug20.docx
Uploaded 08/10/2020
ISRCTN11634296_PIS_prospective_V2.0_28Aug20.docx.docx
Uploaded 08/10/2020

Editorial Notes

23/11/2021: The study was stopped due to the delay in the study set up because of Covid-19, and the fact that the CI had to move overseas.
17/05/2021: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/05/2021 to 30/11/2021.
2. The overall end date was changed from 31/08/2021 to 28/02/2022.
3. The intention to publish date was changed from 31/08/2022 to 28/02/2023.
4. The plain English summary was updated to reflect these changes.
19/11/2020: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/11/2020 to 30/05/2021.
2. The overall trial end date was changed from 28/02/2021 to 31/08/2021.
3. The intention to publish date was changed from 28/02/2022 to 31/08/2022.
08/10/2020: Uploaded protocol Version 1.0, 29 June 2020 (not peer reviewed). The participant information sheets have been uploaded.
17/09/2020: Trial's existence confirmed by North West - Greater Manchester West Research Ethics Committee.